

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. 7)*

MERIT MEDICAL SYSTEMS, INC.

(Name of Issuer)

Common Stock, no par value

(Title of Class of Securities)

58988910

(CUSIP Number)

John E. Runnells
The Vertical Group, L.P.
18 Bank Street
Summit, NJ 07901

(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)

April 14, 2000

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box / /.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule including all exhibits. Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the act (however, see the Notes).

SCHEDULE 13D

=====

CUSIP NO. 58988910

Page 2 of 6 Pages

=====

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Vertical Fund Associates, L.P.

=====

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) | |
(b) | |

=====

3 SEC USE ONLY

=====

4 SOURCE OF FUNDS*
WC

=====

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS | |
IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

6	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7 SOLE VOTING POWER 682,550
	8 SHARED VOTING POWER
	9 SOLE DISPOSITIVE POWER 682,550
	10 SHARED DISPOSITIVE POWER
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 682,550
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES <input type="checkbox"/>
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 8.9%
14	TYPE OF REPORTING PERSON* PN

SCHEDULE 13D

CUSIP NO. 58988910

Page 3 of 6 Pages

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Vertical Life Sciences, L.P.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a)
(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS* WC

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS
IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

NUMBER OF SHARES 7 SOLE VOTING POWER
BENEFICIALLY OWNED BY 390,850
EACH REPORTING PERSON
WITH 8 SHARED VOTING POWER

9 SOLE DISPOSITIVE POWER
390,850

10 SHARED DISPOSITIVE POWER

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
390,850

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)
EXCLUDES CERTAIN SHARES

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 5.1%

14 TYPE OF REPORTING PERSON*
PN

SCHEDULE 13D

CUSIP NO. 58988910

Page 4 of 6 Pages

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Stephen D. Baksa

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a)
(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS*
PF

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS
IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION
U.S.A.

NUMBER OF SHARES 7 SOLE VOTING POWER
BENEFICIALLY OWNED BY 50,000
EACH REPORTING PERSON
WITH

8 SHARED VOTING POWER
1,073,400

9 SOLE DISPOSITIVE POWER
50,000

10 SHARED DISPOSITIVE POWER
1,073,400

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,123,400

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)
EXCLUDES CERTAIN SHARES

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 14.6%

14 TYPE OF REPORTING PERSON*
IN

This Amendment No. 7 to Statement on Schedule 13D (as heretofore amended, the "Statement") with respect to the Common Stock of Merit Medical Systems, Inc. (the "Issuer") ("MMSI Common Stock") is filed by Vertical Fund Associates, L.P. ("Associates") and Vertical Life Sciences, L.P. ("Life Sciences") (together, the "Partnerships") and Stephen D. Baksa ("Baksa") (the Partnerships and Baksa being hereinafter referred to collectively as the "Reporting Persons") in order to amend Items 3 and 5 of the Statement to read in their entirety as set forth below. No change is made to the other Items contained in the Statement.

Item 3. Source and Amount of Funds or Other Consideration.

As of April 18, 2000, Associates owned 682,550 shares of MMSI Common Stock, which it acquired at an aggregate cost of \$4,527,569, Life Sciences owned 390,850 shares of MMSI Common Stock, which it acquired at an aggregate cost of \$2,779,174, and Baksa owned 50,000 shares of MMSI Common Stock, which he acquired at an aggregate cost of \$361,562. All of the shares of MMSI Common Stock owned by the Reporting Persons are hereinafter referred to as the "Shares". The source of funds used by each Partnership to acquire the Shares owned by it was such Partnership's internal cash funds. The source of funds used by Baksa to acquire the Shares owned by him was his personal funds.

Item 5. Interest in Securities of the Issuer.

(a) and (b) Of the total Shares beneficially owned by all the Reporting Persons, 682,550 shares (approximately 8.9% of the total outstanding) are directly and beneficially owned by Associates, 390,850 shares (approximately 5.1% of the total outstanding) are directly and beneficially owned by Life Sciences, and 50,000 shares (approximately 0.7% of the total outstanding) are directly and beneficially owned by Baksa. Subject to the next succeeding paragraph, each Reporting Person has the sole power to vote or direct the vote and to dispose or direct the disposition of the Shares directly and beneficially owned by such Reporting Person.

In addition, The Vertical Group, L.P. ("Group") may be deemed to be the beneficial owner of all 1,073,400 Shares (approximately 14.0% of the total outstanding) collectively owned by the two Partnerships because, as the sole general partner of both Partnerships, Group has the sole power to vote or direct the vote and to dispose or direct the disposition of such Shares, and each of the Individuals (as defined in response to Item 2), including Baksa, may be deemed to be the beneficial owner of all 1,073,400 Shares (approximately 14.0% of the total outstanding) collectively owned by the two Partnerships because, as a general partner of Group (which is the sole general partner of both Partnerships), each such Individual shares the power (which may be exercised by any one of such Individuals acting alone) to vote or direct the vote and to dispose or direct the disposition of such Shares.

(c) In the 60 days preceding the date of this Amendment No. 7, the Reporting Persons effected the following transactions in MMSI Common Stock:

Date	Reporting Person	Number of Shares	Purchase or Sale	Price Per Share
April 13, 2000	Associates	15,000	Purchase	\$5.25
April 14, 2000	Associates	155,000	Purchase	\$5.67
April 17, 2000	Associates	50,000	Purchase	\$5.12
April 17, 2000	Life Sciences	30,000	Purchase	\$5.12
April 14, 2000	Baksa	25,000	Sale	\$5.88

(d) and (e) Not applicable.

Signature.

After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this Amendment No. 7 to Statement on Schedule 13D is true, complete and correct.

April 18, 2000

VERTICAL FUND ASSOCIATES, L.P.

BY: THE VERTICAL GROUP, L.P.
General Partner

By: /s/ John E. Runnells

John E. Runnells
General Partner

VERTICAL LIFE SCIENCES, L.P.
BY: THE VERTICAL GROUP, L.P.
General Partner

By: /s/ John E. Runnells

John E. Runnells
General Partner

/s/ Stephen D. Baksa

Stephen D. Baksa